Voyager Therapeutics Inc.
VYGR | NASDAQ
$3.08
-$0.01 (-0.32%)
At close: Sep 21, 2026, 4:00 PM ET
$3.09
+$0.01 (+0.32%)
Pre-market:
Sep 22, 2026, 7:00 AM ET
-0.32%
(1D)Rating
Updated: Aug 21, 2026Key Statistics
Market Data
Market Cap $186.1M
1D Range
3.05 3.13
52W Range
2.94 5.55
Valuation (TTM)
PE -1.70
PB 1.21
EV/EBITDA -0.99
Valuation (NTM)
Forward PE N/A
Forward PEG 0.07
Price Target $14.40
Cash Flow
FCF Yield -83.2%
SBC Adj. FCF Yield -90.9%
SBC Impact -9.3%
Margins
Gross Margin -104.2%
Operating Margin -340.1%
FCF Margin -449.4%
Growth (CAGR)
Revenue 3Y | 5Y -43.9% |
-23.6%
Dil EPS 3Y | 5Y -92.8% |
-85.8%
FCF 3Y | 5Y -67.9% |
-133.0%
Returns
ROA -54.5%
ROE -57.9%
ROIC -62.4%
Financial Health
Net Cash
$83.77M
Current Ratio 7.51
Interest Coverage 0.00
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Voyager Therapeutics, Inc. operates as a gene therapy company, concentrating its efforts on developing innovative treatments and pioneering advanced platform technologies. Its leading clinical asset, ...
Sector Healthcare
Industry Biotechnology
Employees 141
IPO Date Nov 10, 2015
Website www.voyagertherapeutics.com
Fiscal Year January - December
Latest News
No news articles available yet.
Analyst Summary
# of Analysts
1
Consensus
Buy
Price Target
$18
Upside
+484.42%
Buy (1)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove VYGR